RS58187B1 - Amidom-supstituisana heterociklična jedinjenja korisna kao modulatori il-12, il-23 i/ili ifn-alfa - Google Patents
Amidom-supstituisana heterociklična jedinjenja korisna kao modulatori il-12, il-23 i/ili ifn-alfaInfo
- Publication number
- RS58187B1 RS58187B1 RS20181428A RSP20181428A RS58187B1 RS 58187 B1 RS58187 B1 RS 58187B1 RS 20181428 A RS20181428 A RS 20181428A RS P20181428 A RSP20181428 A RS P20181428A RS 58187 B1 RS58187 B1 RS 58187B1
- Authority
- RS
- Serbia
- Prior art keywords
- substituted
- mmol
- case
- 6alkyl
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723840P | 2012-11-08 | 2012-11-08 | |
| PCT/US2013/068846 WO2014074661A1 (en) | 2012-11-08 | 2013-11-07 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES |
| EP13811640.5A EP2922846B1 (en) | 2012-11-08 | 2013-11-07 | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn-alpha |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS58187B1 true RS58187B1 (sr) | 2019-03-29 |
Family
ID=49876960
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20181428A RS58187B1 (sr) | 2012-11-08 | 2013-11-07 | Amidom-supstituisana heterociklična jedinjenja korisna kao modulatori il-12, il-23 i/ili ifn-alfa |
| RS20220589A RS63328B1 (sr) | 2012-11-08 | 2013-11-07 | Amidom-supstituisana heterociklična jedinjenja korisna kao modulatori il-12, il-23 i/ili ifn alfa odgovora |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20220589A RS63328B1 (sr) | 2012-11-08 | 2013-11-07 | Amidom-supstituisana heterociklična jedinjenja korisna kao modulatori il-12, il-23 i/ili ifn alfa odgovora |
Country Status (39)
Families Citing this family (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014074670A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα |
| HUE059409T2 (hu) * | 2012-11-08 | 2022-11-28 | Bristol Myers Squibb Co | Amidszubsztituált heterociklusos vagyületek mint IL-12-, IL-23- és/vagy IFN-alfa-reakciók modulátorai |
| TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| WO2015089143A1 (en) | 2013-12-10 | 2015-06-18 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| US9834548B2 (en) | 2014-02-14 | 2017-12-05 | Portola Pharmaceuticals, Inc. | Pyridazine compounds as JAK inhibitors |
| US10570096B2 (en) * | 2015-11-26 | 2020-02-25 | Novartis Ag | Diamino pyridine derivatives |
| WO2018071794A1 (en) | 2016-10-14 | 2018-04-19 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| EP3528816A4 (en) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| EP3555111B1 (en) * | 2016-12-13 | 2022-01-26 | Bristol-Myers Squibb Company | Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of il-12, il-23, and/or ifn alpha responses |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| EP4338802A3 (en) | 2017-03-08 | 2024-09-04 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors, uses, and methods for production thereof |
| EP3601268B1 (en) | 2017-03-30 | 2021-03-17 | Bristol-Myers Squibb Company | Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
| WO2019103952A1 (en) * | 2017-11-21 | 2019-05-31 | Bristol-Myers Squibb Company | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
| UY38144A (es) | 2018-03-12 | 2019-10-31 | Abbvie Inc | Inhibidores de la señalización mediada por tirosina cinasa |
| KR102741437B1 (ko) * | 2018-03-22 | 2024-12-10 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 피리딘을 포함하는 헤테로시클릭 화합물 |
| JP2021525734A (ja) * | 2018-05-31 | 2021-09-27 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ６−（シクロプロパンカルボキサミド）−４−（（２−メトキシ−３−（１−メチル−１ｈ−１，２，４−トリアゾール−３−イル）フェニル）アミノ）−ｎ−（メチル−ｄ３）ピリダジン−３−カルボキサミドの結晶形態 |
| TWI842978B (zh) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| GB201816369D0 (en) | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
| US11414431B2 (en) | 2018-10-15 | 2022-08-16 | Nimbus Lakshmi, Inc. | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors |
| WO2020086616A1 (en) * | 2018-10-22 | 2020-04-30 | Fronthera U.S. Pharmaceuticals Llc | Tyk2 inhibitors and uses thereof |
| AU2019373203B2 (en) * | 2018-10-30 | 2024-10-24 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha |
| CN113271938A (zh) | 2018-11-30 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| US11174264B2 (en) | 2019-01-23 | 2021-11-16 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| CN115448910B (zh) * | 2019-01-28 | 2024-04-19 | 江苏豪森药业集团有限公司 | 一种哒嗪类衍生物抑制剂、其制备方法和应用 |
| CN111484480B (zh) * | 2019-01-29 | 2023-08-11 | 上海翰森生物医药科技有限公司 | 一种多环类衍生物抑制剂、其制备方法和应用 |
| KR20210121140A (ko) * | 2019-01-30 | 2021-10-07 | 브리스톨-마이어스 스큅 컴퍼니 | 아미드-이치환된 피리딘 또는 피리다진 화합물 |
| WO2020222773A1 (en) | 2019-04-30 | 2020-11-05 | Celgene Corporation | Combination therapies comprising apremilast and tyk2 inhibitors |
| US11357775B2 (en) | 2019-04-30 | 2022-06-14 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
| WO2020251911A1 (en) | 2019-06-12 | 2020-12-17 | Bristol-Myers Squibb Company | Crystalline salt forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide |
| WO2021011513A1 (en) | 2019-07-16 | 2021-01-21 | Bristol-Myers Squibb Company | Prodrugs in the modulation of interleukin |
| US12428395B2 (en) | 2019-08-01 | 2025-09-30 | Sperogenix Therapeutics Limited | Heterocyclic compounds as kinase inhibitor and uses thereof |
| CA3150108A1 (en) | 2019-09-13 | 2021-03-18 | Neelu Kaila | Hpk1 antagonists and uses thereof |
| CA3151137A1 (en) | 2019-09-18 | 2021-03-25 | Sherif Ibrahim Farag Badawy | Dosage forms for tyk2 inhibitors |
| WO2021129467A1 (zh) * | 2019-12-27 | 2021-07-01 | 苏州科睿思制药有限公司 | 一种bms-986165晶型及其制备方法和用途 |
| WO2021143498A1 (zh) * | 2020-01-19 | 2021-07-22 | 苏州科睿思制药有限公司 | 一种Deucravacitinib的晶型及其制备方法和用途 |
| WO2021143430A1 (zh) * | 2020-01-19 | 2021-07-22 | 苏州科睿思制药有限公司 | 一种bms-986165盐酸盐晶型及其制备方法和用途 |
| WO2021170046A1 (en) * | 2020-02-26 | 2021-09-02 | Beigene, Ltd. | Tyk-2 inhibitor |
| KR20220152303A (ko) * | 2020-03-11 | 2022-11-15 | 베이징 이노케어 파마 테크 씨오., 엘티디. | Tyk2 활성을 저해하기 위한 헤테로시클릭 화합물 |
| WO2021204626A1 (en) * | 2020-04-06 | 2021-10-14 | Almirall, S.A. | Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors |
| GB202005114D0 (en) | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
| CN113563309B (zh) * | 2020-04-28 | 2024-12-13 | 浙江海正药业股份有限公司 | 吡啶类衍生物及其制备方法和用途 |
| EP4143180A1 (en) * | 2020-04-28 | 2023-03-08 | Bristol-Myers Squibb Company | Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators |
| CN113735836B (zh) * | 2020-05-28 | 2023-05-30 | 江苏先声药业有限公司 | 哒嗪类化合物及其应用 |
| CN113735837B (zh) * | 2020-05-28 | 2023-09-01 | 江苏先声药业有限公司 | 哒嗪类化合物及其用途 |
| CN113773262B (zh) * | 2020-06-09 | 2024-08-09 | 江苏先声药业有限公司 | 哒嗪类化合物 |
| TW202200561A (zh) | 2020-06-22 | 2022-01-01 | 英屬開曼群島商百濟神州有限公司 | Tyk-2抑制劑 |
| CN113968846A (zh) * | 2020-07-24 | 2022-01-25 | 上海翰森生物医药科技有限公司 | 一种哒嗪类衍生物的盐、晶型及其制备方法和应用 |
| WO2022017494A1 (zh) * | 2020-07-24 | 2022-01-27 | 上海翰森生物医药科技有限公司 | 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用 |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| CN114057651B (zh) * | 2020-07-31 | 2025-05-27 | 正大天晴药业集团股份有限公司 | 含酰胺基的tyk2抑制剂化合物 |
| WO2022021684A1 (zh) * | 2020-07-31 | 2022-02-03 | 苏州科睿思制药有限公司 | 一种bms-986165盐酸盐晶型csv及其制备方法和用途 |
| JP2023541997A (ja) * | 2020-09-18 | 2023-10-04 | ブリストル－マイヤーズ スクイブ カンパニー | 膨潤性コアを含むｔｙｋ２阻害薬の剤形 |
| WO2022083649A1 (zh) * | 2020-10-20 | 2022-04-28 | 杭州领业医药科技有限公司 | 哒嗪衍生物的晶型 |
| US12331046B2 (en) | 2020-10-23 | 2025-06-17 | Nimbus Clotho, Inc. | CTPS1 inhibitors and uses thereof |
| CN120887875A (zh) * | 2020-11-12 | 2025-11-04 | 上海睿跃生物科技有限公司 | 酪氨酸激酶2(tyk2)降解化合物和使用方法 |
| WO2022105771A1 (zh) * | 2020-11-17 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 含氮杂环类衍生物、其制备方法及其在医药上的应用 |
| WO2022121868A1 (zh) * | 2020-12-08 | 2022-06-16 | 正大天晴药业集团股份有限公司 | 含酰胺基和杂环烷基的tyk2抑制剂化合物 |
| US12492184B2 (en) | 2020-12-22 | 2025-12-09 | InventisBio Co., Ltd. | Heteroaryl compounds, preparation methods and uses thereof |
| CN116829549A (zh) * | 2021-01-29 | 2023-09-29 | 百时美施贵宝公司 | 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d３)哒嗪-3-甲酰胺的晶型 |
| KR20230153387A (ko) | 2021-02-02 | 2023-11-06 | 리미널 바이오사이언시스 리미티드 | Gpr84 길항제 및 이의 용도 |
| MX2023009059A (es) | 2021-02-02 | 2023-09-15 | Liminal Biosciences Ltd | Antagonistas de gpr84 y usos de estos. |
| TW202233600A (zh) * | 2021-02-06 | 2022-09-01 | 大陸商正大天晴藥業集團股份有限公司 | 含聯環的ｔｙｋ２抑制劑化合物、藥物組合物及其用途 |
| CN114907326B (zh) * | 2021-02-06 | 2025-02-18 | 正大天晴药业集团股份有限公司 | 含酰胺基和联环的tyk2抑制剂化合物 |
| CN117120090A (zh) | 2021-02-12 | 2023-11-24 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| KR20230159419A (ko) | 2021-02-19 | 2023-11-21 | 수도 바이오사이언시즈 리미티드 | Tyk2 억제제 및 이의 용도 |
| IL305165A (en) | 2021-02-19 | 2023-10-01 | Sudo Biosciences Ltd | Tyk2 inhibitors and uses thereof |
| CN117295737A (zh) | 2021-03-05 | 2023-12-26 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| CA3213816A1 (en) | 2021-03-16 | 2022-09-22 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
| WO2022212181A1 (en) | 2021-03-29 | 2022-10-06 | Bristol-Myers Squibb Company | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
| WO2022213062A1 (en) | 2021-03-29 | 2022-10-06 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| CN117177960B (zh) * | 2021-03-30 | 2025-01-28 | 浙江文达医药科技有限公司 | 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途 |
| CN115197196B (zh) * | 2021-04-06 | 2024-06-18 | 扬子江药业集团有限公司 | Tyk2抑制剂及其用途 |
| KR20240007155A (ko) | 2021-04-09 | 2024-01-16 | 님버스 클리오, 인코포레이티드 | Cbl-b 조절제 및 이의 용도 |
| WO2022233286A1 (zh) | 2021-05-04 | 2022-11-10 | 上海喆邺生物科技有限公司 | 一类含氮杂环吡啶类化合物 |
| MX2023013445A (es) | 2021-05-14 | 2023-12-14 | Bristol Myers Squibb Co | Compuestos heterociclicos sustituidos. |
| EP4337649A1 (en) | 2021-05-14 | 2024-03-20 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| KR20240007242A (ko) * | 2021-05-14 | 2024-01-16 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 헤테로시클릭 화합물 |
| WO2022241173A1 (en) | 2021-05-14 | 2022-11-17 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| WO2022253335A1 (zh) * | 2021-06-02 | 2022-12-08 | 南京明德新药研发有限公司 | 含磺酰基的芳基类化合物及其应用 |
| CN115466289A (zh) * | 2021-06-11 | 2022-12-13 | 爱科诺生物医药(香港)有限公司 | 具有tyk2抑制活性的化合物，包含其的药物组合物，及其应用 |
| IL309572A (en) * | 2021-06-22 | 2024-02-01 | Medshine Discovery Inc | Sulfoximine compound and use thereof |
| CN117794911A (zh) * | 2021-07-15 | 2024-03-29 | 南京明德新药研发有限公司 | 含硫/磷的芳基类化合物及其应用 |
| KR20240050380A (ko) | 2021-08-20 | 2024-04-18 | 브리스톨-마이어스 스큅 컴퍼니 | 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의결정 형태 |
| WO2023027948A1 (en) * | 2021-08-21 | 2023-03-02 | Relay Therapeutics, Inc. | Jak2 inhibitors and methods of use thereof |
| EP4404930A1 (en) | 2021-09-23 | 2024-07-31 | Bristol-Myers Squibb Company | Methods of treating hair-loss disorders with tyk2 inhibitors |
| US20240390369A1 (en) | 2021-09-30 | 2024-11-28 | Bristol-Myers Squibb Company | Methods for determining responsiveness to tyk2 inhibitors |
| JP2024539280A (ja) | 2021-10-25 | 2024-10-28 | カイメラ セラピューティクス， インコーポレイテッド | Ｔｙｋ２分解剤およびそれらの使用 |
| WO2023076515A1 (en) | 2021-10-28 | 2023-05-04 | Bristol-Myers Squibb Company | Topical formulations of deucravacitinib |
| WO2023102085A1 (en) | 2021-12-01 | 2023-06-08 | Teva Czech Industries S.R.O. | Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates |
| WO2023109954A1 (en) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
| WO2023108536A1 (en) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
| CN116283928A (zh) * | 2021-12-20 | 2023-06-23 | 艾立康药业股份有限公司 | 一种哒嗪类化合物、其制备方法和应用 |
| EP4206196A1 (en) | 2021-12-29 | 2023-07-05 | Almirall S.A. | Pyrimidine substituted derivatives as tyk2 inhibitors |
| CN116693449A (zh) | 2022-03-04 | 2023-09-05 | 上海致根医药科技有限公司 | 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用 |
| CN119233971A (zh) * | 2022-05-31 | 2024-12-31 | 上海华汇拓医药科技有限公司 | 一种哒嗪类化合物、其制备方法和用途 |
| CN117447411B (zh) * | 2022-07-18 | 2025-12-23 | 苏州鹏旭医药科技有限公司 | 一种杂环药物中间体的合成方法 |
| WO2024020221A1 (en) | 2022-07-21 | 2024-01-25 | Arvinas Operations, Inc. | Modulators of tyk2 proteolysis and associated methods of use |
| JP2025527248A (ja) | 2022-08-02 | 2025-08-20 | リミナル・バイオサイエンシーズ・リミテッド | 置換ピリドンｇｐｒ８４アンタゴニスト及びその使用 |
| TW202416950A (zh) | 2022-08-02 | 2024-05-01 | 英商利米那生物科技有限公司 | 雜芳基甲醯胺及相關gpr84拮抗劑及其用途 |
| IL318577A (en) | 2022-08-02 | 2025-03-01 | Liminal Biosciences Ltd | ARYL-TRIAZOLYL AND RELATED GPR84 ANTAGONISTS AND THEIR USES |
| JP2025537201A (ja) | 2022-11-08 | 2025-11-14 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ヘテロ環式化合物 |
| AR131375A1 (es) | 2022-12-16 | 2025-03-12 | Alembic Pharmaceuticals Ltd | Ligandos de pseudoquinasa tyk2 y sus usos |
| CN116284040B (zh) * | 2023-01-05 | 2024-05-28 | 华润医药研究院（深圳）有限公司 | 含氮杂环类化合物及其医药用途 |
| WO2024165000A1 (zh) * | 2023-02-07 | 2024-08-15 | 上海华汇拓医药科技有限公司 | 一种哒嗪类化合物、其制备方法和用途 |
| CN118724752B (zh) * | 2023-03-29 | 2025-11-28 | 重庆博腾制药科技股份有限公司 | 一种酪氨酸激酶抑制剂中间体、制备方法及其应用 |
| CN116162093B (zh) * | 2023-04-25 | 2023-06-23 | 中南大学湘雅医院 | 一种tyk2抑制剂化合物及其用途 |
| WO2024236491A1 (en) * | 2023-05-15 | 2024-11-21 | Glenmark Life Sciences Limited | Process for the preparation of deucravacitinib, and crystalline forms thereof |
| CN119080742A (zh) * | 2023-06-05 | 2024-12-06 | 甘莱制药有限公司 | 脂质合成的杂环调节剂的工业化制备 |
| WO2024257023A1 (en) | 2023-06-14 | 2024-12-19 | Alembic Pharmaceuticals Limited | Tyk2 pseudokinase ligands and uses thereof |
| CN117447353B (zh) * | 2023-09-21 | 2025-12-30 | 爱斯特（成都）生物制药股份有限公司 | 一种氘可来昔替尼中间体的制备方法 |
| WO2025062372A1 (en) | 2023-09-21 | 2025-03-27 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors for use in the treatment of inflammatory bowel disease |
| EP4538259A1 (en) | 2023-10-09 | 2025-04-16 | Farmhispania Group, S.L. | Processes for the preparation of deucravacitinib |
| WO2025131031A1 (zh) * | 2023-12-22 | 2025-06-26 | 上海奥博生物医药股份有限公司 | 一种TyK2抑制剂及其中间体的制备方法 |
| WO2025173029A1 (en) * | 2024-02-14 | 2025-08-21 | Natco Pharma Limited | An improved process for the preparation of deucravacitinib |
| WO2025186427A1 (en) | 2024-03-08 | 2025-09-12 | Curia Spain, S.A.U. | Process for the preparation of deucravacitinib and intermediates thereof and method for purifying deucravacitinib |
| CN118593504B (zh) * | 2024-06-03 | 2025-03-18 | 北京大学第三医院（北京大学第三临床医学院） | 氘可来昔替尼或其盐在制备pvns药物方面的新用途 |
| CN119059972B (zh) * | 2024-08-12 | 2025-10-28 | 武汉九州钰民医药科技有限公司 | 一种btk抑制剂吡托布鲁替尼的合成方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000075113A1 (en) | 1999-06-09 | 2000-12-14 | Yamanouchi Pharmaceutical Co., Ltd. | Novel heterocyclic carboxamide derivatives |
| JP4622047B2 (ja) * | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | 新規なヘテロ環カルボキサミド誘導体 |
| WO2000076980A1 (en) | 1999-06-10 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
| US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| CA2356544C (en) | 2000-10-03 | 2006-04-04 | Warner-Lambert Company | Pyridotriazines and pyridopyridazines |
| KR20050037552A (ko) | 2002-07-15 | 2005-04-22 | 와이어쓰 | Ｔ 헬퍼(ｔｈ) 세포 발생 및 기능을 조절하는 방법 및조성물 |
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| US20130096104A1 (en) | 2010-03-17 | 2013-04-18 | Genentech, Inc. | Imidazopyridine compounds, compositions and methods of use |
| TW201217387A (en) | 2010-09-15 | 2012-05-01 | Hoffmann La Roche | Azabenzothiazole compounds, compositions and methods of use |
| WO2012066061A1 (en) | 2010-11-19 | 2012-05-24 | F. Hoffmann-La Roche Ag | Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors |
| WO2013047813A1 (ja) * | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | １，２，４－トリアジン－６－カルボキサミド誘導体 |
| JP6109192B2 (ja) * | 2012-01-10 | 2017-04-05 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ピリダジンアミド化合物及びｓｙｋ阻害剤としてのそれらの使用 |
| UY34807A (es) | 2012-05-16 | 2013-12-31 | Novartis Ag | Derivados monocíclicos de heteroarilcicloalquil- diamina |
| US9040530B2 (en) * | 2012-06-22 | 2015-05-26 | Portola Pharmaceuticals, Inc. | 1,2,4-triazine-6-carboxamide kinase inhibitors |
| HK1211024A1 (en) * | 2012-10-19 | 2016-05-13 | 霍夫曼-拉罗奇有限公司 | Inhibitors of syk |
| HUE059409T2 (hu) * | 2012-11-08 | 2022-11-28 | Bristol Myers Squibb Co | Amidszubsztituált heterociklusos vagyületek mint IL-12-, IL-23- és/vagy IFN-alfa-reakciók modulátorai |
| WO2014074670A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα |
| WO2014074660A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES |
| TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| EP3601268B1 (en) | 2017-03-30 | 2021-03-17 | Bristol-Myers Squibb Company | Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
-
2013
- 2013-11-07 HU HUE18197550A patent/HUE059409T2/hu unknown
- 2013-11-07 DK DK18197550.9T patent/DK3495358T3/da active
- 2013-11-07 MY MYPI2020005025A patent/MY194668A/en unknown
- 2013-11-07 US US14/441,183 patent/US9505748B2/en not_active Ceased
- 2013-11-07 ES ES18197550T patent/ES2914793T3/es active Active
- 2013-11-07 MY MYPI2022004735A patent/MY198262A/en unknown
- 2013-11-07 EP EP22165094.8A patent/EP4071144A1/en active Pending
- 2013-11-07 US US16/201,653 patent/USRE47929E1/en active Active
- 2013-11-07 EP EP13811640.5A patent/EP2922846B1/en active Active
- 2013-11-07 KR KR1020157014694A patent/KR102195194B1/ko active Active
- 2013-11-07 AR ARP130104091A patent/AR094452A1/es active IP Right Grant
- 2013-11-07 HU HUE13811640A patent/HUE041750T2/hu unknown
- 2013-11-07 LT LTEP13811640.5T patent/LT2922846T/lt unknown
- 2013-11-07 EA EA201590917A patent/EA028814B1/ru not_active IP Right Cessation
- 2013-11-07 PL PL18197550T patent/PL3495358T3/pl unknown
- 2013-11-07 RS RS20181428A patent/RS58187B1/sr unknown
- 2013-11-07 PT PT13811640T patent/PT2922846T/pt unknown
- 2013-11-07 ES ES13811640T patent/ES2702148T3/es active Active
- 2013-11-07 HR HRP20220766TT patent/HRP20220766T1/hr unknown
- 2013-11-07 NZ NZ708859A patent/NZ708859A/en unknown
- 2013-11-07 SM SM20190001T patent/SMT201900001T1/it unknown
- 2013-11-07 TR TR2018/20824T patent/TR201820824T4/tr unknown
- 2013-11-07 MY MYPI2015701475A patent/MY175448A/en unknown
- 2013-11-07 SG SG10201706985UA patent/SG10201706985UA/en unknown
- 2013-11-07 LT LTEP18197550.9T patent/LT3495358T/lt unknown
- 2013-11-07 SI SI201331986T patent/SI3495358T1/sl unknown
- 2013-11-07 DK DK13811640.5T patent/DK2922846T3/en active
- 2013-11-07 TW TW102140572A patent/TWI605041B/zh active
- 2013-11-07 SM SM20220258T patent/SMT202200258T1/it unknown
- 2013-11-07 HR HRP20181937TT patent/HRP20181937T1/hr unknown
- 2013-11-07 PE PE2015000607A patent/PE20150944A1/es active IP Right Grant
- 2013-11-07 AU AU2013341186A patent/AU2013341186B2/en active Active
- 2013-11-07 SG SG10201706897TA patent/SG10201706897TA/en unknown
- 2013-11-07 CN CN201380069692.9A patent/CN104884454B/zh active Active
- 2013-11-07 WO PCT/US2013/068846 patent/WO2014074661A1/en not_active Ceased
- 2013-11-07 EP EP18197550.9A patent/EP3495358B8/en active Active
- 2013-11-07 CA CA2890981A patent/CA2890981C/en active Active
- 2013-11-07 UY UY0001035126A patent/UY35126A/es unknown
- 2013-11-07 BR BR112015010102-0A patent/BR112015010102B1/pt active IP Right Grant
- 2013-11-07 MA MA38072A patent/MA38072A1/fr unknown
- 2013-11-07 JP JP2015541883A patent/JP6407159B2/ja active Active
- 2013-11-07 PL PL13811640T patent/PL2922846T3/pl unknown
- 2013-11-07 SG SG11201503399XA patent/SG11201503399XA/en unknown
- 2013-11-07 SI SI201331219T patent/SI2922846T1/sl unknown
- 2013-11-07 PT PT181975509T patent/PT3495358T/pt unknown
- 2013-11-07 RS RS20220589A patent/RS63328B1/sr unknown
- 2013-11-07 MX MX2015005731A patent/MX2015005731A/es active IP Right Grant
-
2015
- 2015-05-04 IL IL238610A patent/IL238610A0/en active IP Right Grant
- 2015-05-06 MX MX2020003156A patent/MX2020003156A/es unknown
- 2015-05-06 PH PH12015501004A patent/PH12015501004B1/en unknown
- 2015-05-07 CL CL2015001231A patent/CL2015001231A1/es unknown
- 2015-06-05 ZA ZA2015/04052A patent/ZA201504052B/en unknown
-
2016
- 2016-10-10 US US15/289,437 patent/US10000480B2/en active Active
-
2017
- 2017-02-17 AU AU2017201076A patent/AU2017201076B2/en active Active
-
2018
- 2018-05-15 US US15/979,770 patent/US10526321B2/en active Active
- 2018-05-16 JP JP2018094837A patent/JP6585231B2/ja active Active
- 2018-11-19 AU AU2018267545A patent/AU2018267545B2/en active Active
- 2018-12-14 CY CY20181101343T patent/CY1121188T1/el unknown
-
2019
- 2019-09-04 JP JP2019161215A patent/JP2020002157A/ja active Pending
- 2019-11-18 US US16/687,279 patent/US11021475B2/en active Active
-
2020
- 2020-06-15 AU AU2020203967A patent/AU2020203967B2/en active Active
-
2021
- 2021-04-29 US US17/244,938 patent/US20220356180A1/en not_active Abandoned
-
2022
- 2022-06-02 CY CY20221100391T patent/CY1125220T1/el unknown
-
2023
- 2023-07-24 NL NL301238C patent/NL301238I2/nl unknown
- 2023-07-27 CY CY2023017C patent/CY2023017I2/el unknown
- 2023-08-10 HU HUS2300025C patent/HUS2300025I1/hu unknown
- 2023-08-14 FR FR23C1030C patent/FR23C1030I2/fr active Active
- 2023-08-23 LT LTPA2023523C patent/LTC2922846I2/lt unknown
- 2023-08-25 NO NO2023032C patent/NO2023032I1/no unknown
- 2023-08-28 FI FIC20230028C patent/FIC20230028I1/fi unknown
-
2024
- 2024-09-10 US US18/830,387 patent/US20250243193A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11021475B2 (en) | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | |
| AU2014347275B2 (en) | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNalpha responses | |
| HK40083010A (en) | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses | |
| HK40010074B (en) | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses | |
| HK40010074A (en) | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses | |
| HK1215255B (en) | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn-alpha | |
| HK1226400B (en) | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses |